Search This Blog

Tuesday, June 29, 2021

FDA Clears Cullinan Oncology Application for Trials for Tumor-Targeted Antibody

 

  • CLN-619 will be the first MICA/B-targeted antibody to enter human clinical trials

  • Cullinan will initiate a FIH trial in 3Q21, including a dose escalation cohort followed by dose expansion cohorts as a monotherapy and in combination with checkpoint inhibitor therapy

Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)